MDxHealth SA (NASDAQ:MDXH) Given Average Rating of “Moderate Buy” by Analysts

MDxHealth SA (NASDAQ:MDXH) has been assigned a consensus rating of “Moderate Buy” from the five research firms that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $7.75.

Several research firms recently commented on MDXH. Weiss Ratings restated a “sell (d-)” rating on shares of MDxHealth in a report on Monday, December 29th. BTIG Research reissued a “buy” rating and issued a $7.00 target price on shares of MDxHealth in a research note on Tuesday, December 23rd. Lake Street Capital upped their price target on shares of MDxHealth from $7.00 to $9.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Finally, TD Cowen increased their price target on MDxHealth from $5.00 to $7.00 and gave the company a “buy” rating in a report on Thursday, November 13th.

MDxHealth Price Performance

MDxHealth stock opened at $3.63 on Friday. The company has a market cap of $171.66 million, a price-to-earnings ratio of -5.67 and a beta of 1.64. MDxHealth has a 12 month low of $1.35 and a 12 month high of $5.33. The stock’s 50-day moving average is $3.52 and its 200-day moving average is $3.73.

Hedge Funds Weigh In On MDxHealth

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Intesa Sanpaolo Wealth Management acquired a new stake in MDxHealth in the fourth quarter valued at approximately $36,000. GSA Capital Partners LLP purchased a new position in shares of MDxHealth in the third quarter valued at $48,000. Lido Advisors LLC acquired a new stake in MDxHealth during the 3rd quarter valued at $48,000. Squarepoint Ops LLC purchased a new stake in MDxHealth during the 4th quarter worth $51,000. Finally, Jefferies Financial Group Inc. purchased a new stake in MDxHealth during the 3rd quarter worth $53,000.

About MDxHealth

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.